Who owns Dianthus Therapeutics (DNTH)? Superinvestor holders

2 superinvestors of the 157 tracked here hold Dianthus Therapeutics (DNTH) in their latest 13F filing, with $85.3M between them. Julian and Felix Baker gives it the most weight: 0.42% of the reported portfolio. In their latest reported quarter, Polen Capital team added.

Peter Kolchinsky and Steve Cohen sold out of it in their latest quarter.

Hold it now
2
of 157 tracked
Combined value
$85.3M
Bought / sold
1 / 2
last quarter

Key facts

Superinvestors holding it
2 of 157
Biggest holder
Julian and Felix Baker, $83.1M
Largest weight
Julian and Felix Baker, 0.42%of their portfolio
Combined value
$85.3M
Bought last quarter
1
Sold last quarter
2

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding DNTH, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Julian and Felix BakerBaker Bros. Advisors0.42%$83.1M852.16KNo change0Q2 2026
2Polen Capital teamPolen Capital Management0.02%$2.2M24.93K▲ Added 167%+15.59KQ3 2026

Sold out last quarter

Quarter by quarter

Superinvestor ownership of DNTH by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 202692124.93K$2.2M10
Q2 20261571852.16K$83.1M03
Q1 202615734.3M$360.8M30
Q4 202515722.4M$99M01
Q3 202515723.66M$143.9M00
Q2 202515723.66M$68.1M10
Q1 202515612.87M$52M10
Q4 202415611.87M$40.7M01

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of DNTH held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Polen Capital team24.93K———————
Julian and Felix Baker·852.16K852.16K789.76K789.76K789.76K——
Peter Kolchinsky·—2.61M1.61M2.87M2.87M2.87M1.87M
Andrew Spokes——836K—————

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own DNTH?

In their latest 13F filings: Julian and Felix Baker (0.42% of the portfolio, $83.1M), Polen Capital team (0.02% of the portfolio, $2.2M).

Who bought DNTH last quarter?

Polen Capital team (added 167%). “Last quarter” is each investor's latest reported quarter.

Who sold DNTH last quarter?

Sold out entirely: Peter Kolchinsky (was $219.2M), Steve Cohen (was $54M).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns Dianthus Therapeutics (DNTH)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/DNTH/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to DNTH by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.